Phase 3 Clinical Trials With Primary Completion Dates in January 2022

This is a list of Phase 3 trials with primary completion dates in January 2022 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
ADIL Adial Pharmaceuticals, Inc. 2022-01-01 Phase 3 NCT04101227 Study to Evaluate AD04 in Adults With Alcohol Use Disorder (AUD) and Selected Serotonin Transporter Polymorphisms
ARNA Arena Pharmaceuticals, Inc. 2022-01-01 Phase 3 NCT03945188 Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
CHHE China Health Industries Holdings, Inc. 2022-01-01 Phase 3 NCT05159947 SPT-07A Injection in Patients With Acute Ischemic Stroke (AIS): A Phase III Clinical Trial
CORT Corcept Therapeutics Incorporated 2022-01-01 Phase 3 NCT04329949 Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
CYDY CytoDyn Inc. 2022-01-01 Phase 3 NCT04901676 Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia
FGEN FibroGen, Inc. 2022-01-01 Phase 3 NCT03263091 Efficacy and Safety of FG-4592 for Treatment of Anemia in Patients With Lower Risk MDS With Low Red Blood Cell Transfusion Burden
MRNS Marinus Pharmaceuticals, Inc. 2022-01-01 Phase 3 NCT04391569 RAndomized Therapy In Status Epilepticus
OBSV ObsEva SA 2022-01-01 Phase 3 NCT03992846 Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.
VRNA Verona Pharma plc 2022-01-01 Phase 3 NCT04542057 A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
ZGNX Zogenix, Inc. 2022-01-01 Phase 3 NCT02823145 An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome